TUCSON, Ariz., June 08, 2022 (Globe NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a everyday living science enterprise advancing precision medicine by means of its innovative transcriptome-broad profiling know-how, announced that it will be sponsoring a keynote presentation at the 7th Annual MarketsandMarkets Biomarker and Companion Diagnostics Convention in San Diego, CA, titled “Implementing Biomarker Approach in Clinical Trials” on June 16th at 9:05 AM PT.
This presentation will characteristic Chetan Deshpande, Director, Biomarker Medical Assay Lead, World wide Solution Development at Pfizer. Mr. Deshpande will go over the issues that are frequently faced in clinical trials and how Pfizer has leveraged HTG’s proprietary gene expression profiling HTG EdgeSeq know-how in various medical trials to get over these challenges.
Information of the Keynote Presentation are underneath:
HTG is accelerating precision medication from analysis to procedure by harnessing the energy of transcriptome-wide profiling to push translational research, scientific diagnostics and targeted therapeutics throughout a wide variety of illness spots.
Constructing on additional than a ten years of revolutionary innovation and partnerships with biopharma leaders and major educational institutes, HTG’s proprietary RNA platform systems are created to make the progress of life science applications and diagnostics additional productive and effective and to unlock a differentiated and disruptive method to transformative drug discovery. For a lot more info visit www.htgmolecular.com.
HTG Investor Get hold of:
Cellphone: (617) 430-7577
E mail: [email protected]